ClinicalTrials.gg
TerminatedNCT00447421Updated Oct 28, 2009Results posted

A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

A Phase 1/2 interventional study of pemetrexed and cisplatin in Small Cell Lung Cancer, Carcinoma, Small Cell and SCLC, sponsored by Eli Lilly and Company. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-28.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Interim results of another trial showed inferior activity of treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing cisplatin in Small Cell Lung Carcinoma — 2 open to participants now, 2 under way, none of them phase 3. Cisplatin · Small Cell Lung Carcinoma.

Enrollment
25th of 32
9 · median 62
Started
2007
with 2 others
Phase 1/2
4 of 33
none open now
Registered
17th of 33
by date
Lead sponsor
2 of 33
Eli Lilly and Company

Among the 33 studies testing cisplatin in Small Cell Lung Carcinoma, this one is the 25th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2007, is one of 4 in phase 1/2, and was the 17th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 33 studies testing cisplatin in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing cisplatin in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.

03

Conditions studied

  • Small Cell Lung Cancer
  • Carcinoma, Small Cell
  • SCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • with diagnosis of Small Cell Lung Cancer.
  • Performance status of 0 to 1 on the performance status schedule.
  • Patients must be at least 18 years of age and have at least a 12-week .
  • No prior chemotherapy and/or prior thoracic radiotherapy.
  • Adequate pulmonary function and organ function.

Exclusion criteria

Exclusion Criteria:

  • Patients with myocardial infarction within the preceding six months.
  • Diagnosis of a serious concomitant systemic disorder.
  • Prior radiotherapy to the lower neck or abdominal region.
  • Significant weight loss.
  • Concurrent administration of any other antitumor therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    A

    Drug: pemetrexed · Drug: cisplatin · Radiation: radiation

Interventions

  • Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation) Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles

    Also known as: LY231514, Alimta

  • Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles

  • Radiationradiation

    Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose

    Time frame: every cycle

  2. Phase 2: Overall Response Rate

    Overall Response Rate (ORR) was defined as the proportion of participants having either a Complete or Partial response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions.

    Time frame: baseline to measured progressive disease

Secondary outcomes

  1. Phase 1: Best Overall Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to measured response

  2. Phase 2: Complete Response Rate

    Complete Response Rate was defined as the proportion of participants having a Complete Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions.

    Time frame: baseline to measured response time

  3. Phase 2: Time to Progressive Disease

    Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

    Time frame: baseline to measured progressive disease

  4. Phase 2: Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: time of response to progressive disease

  5. Phase 2: Overall Survival

    Overall survival was the duration from enrollment to death. For patients who were alive, overall survival was censored at the last contact.

    Time frame: baseline to date of death from any cause

07

Results

Posted Aug 26, 2009
Limitations and caveats
The Study Phase 1 was stopped early based on interim results of another trial, showing inferior activity of pemetrexed/carboplatin compared to etoposide/carboplatin in extensive small cell lung cancer. The Study did not progress to Phase 2.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin
Started9
Completed3
Not completed6
Withdrew: Lack of efficacy1
Withdrew: Adverse event3
Withdrew: Sponsor decision2

Outcome measures

PrimaryPhase 1: Maximum Tolerated Dose
Time frame:
every cycle
Reported as:
Mean · milligrams per square meter

No measurements were reported for this outcome.

PrimaryPhase 2: Overall Response Rate

Overall Response Rate (ORR) was defined as the proportion of participants having either a Complete or Partial response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions.

Time frame:
baseline to measured progressive disease
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryPhase 1: Best Overall Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to measured response
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryPhase 2: Complete Response Rate

Complete Response Rate was defined as the proportion of participants having a Complete Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions.

Time frame:
baseline to measured response time
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryPhase 2: Time to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

Time frame:
baseline to measured progressive disease
Reported as:
Mean · months

No measurements were reported for this outcome.

SecondaryPhase 2: Duration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
time of response to progressive disease
Reported as:
Mean · months

No measurements were reported for this outcome.

SecondaryPhase 2: Overall Survival

Overall survival was the duration from enrollment to death. For patients who were alive, overall survival was censored at the last contact.

Time frame:
baseline to date of death from any cause
Reported as:
Mean · months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin———
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPemetrexed + Cisplatin
VomitingGastrointestinal disorders2/9
AnaemiaBlood and lymphatic system disorders1/9
Abdominal pain upperGastrointestinal disorders1/9
NauseaGastrointestinal disorders1/9
OesophagitisGastrointestinal disorders1/9
FatigueGeneral disorders1/9
MalaiseGeneral disorders1/9
DiverticulitisInfections and infestations1/9
Lung infectionInfections and infestations1/9
PneumoniaInfections and infestations1/9
Most frequent other events
Showing 10 of 94
Most frequent other events
EventPemetrexed + Cisplatin
NauseaGastrointestinal disorders6/9
AnorexiaMetabolism and nutrition disorders5/9
Fluid retentionMetabolism and nutrition disorders5/9
DiarrhoeaGastrointestinal disorders4/9
StomatitisGastrointestinal disorders4/9
FatigueGeneral disorders4/9
HeadacheNervous system disorders4/9
AnaemiaBlood and lymphatic system disorders3/9
LymphopeniaBlood and lymphatic system disorders3/9
ConstipationGastrointestinal disorders3/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pemetrexed + Cisplatin
<=18 years0
Between 18 and 65 years4
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Cisplatin
Female3
Male6
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Cisplatin
Belgium2
Netherlands7
08

Study locations

4 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amsterdam, 1081 HV, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Den Bosch, 5211 NL, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rotterdam, 3075 EA, Netherlands
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2007
First posted
Mar 14, 2007
Start
Feb 2007
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Aug 26, 2009
Last update
Oct 28, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00447421
First posted
Mar 14, 2007
Start date
Feb 2007
Primary completion
May 2008
Completion
May 2008
Results posted
Aug 26, 2009
Last update
Oct 28, 2009

Study contacts

Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion